SCHEMBL5864733

SCHEMBL5864733

COc1cc2ncnc(Nc3cc(Br)c(C)c(Br)c3)c2cc1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 2/20 0.79
MKNK1 Q9BUB5 2/20 0.79
EGFR P00533 16/20 0.76
KDR P35968 4/20 0.71
ABCG2 Q9UNQ0 3/20 0.70
ABCB1 P08183 1/20 0.70
SRC P12931 3/20 0.69
GAK O14976 2/20 0.69
LCK P06239 5/20 0.67
PDGFRB P09619 1/20 0.67
PDGFRA P16234 1/20 0.67
RET P07949 2/20 0.65
ERBB2 P04626 2/20 0.65
KDM4E B2RXH2 1/20 0.65
MAPK13 O15264 1/20 0.65
ABL1 P00519 1/20 0.65
CYP1A2 P05177 1/20 0.65
CDK1 P06493 1/20 0.65
CYP3A4 P08684 1/20 0.65
FBP1 P09467 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925305 0.88 JAK3 (1.00) JAK3MKNK1EGFRKDRABCG2
SCHEMBL323445 0.88 JAK3 (1.00) JAK3MKNK1EGFRKDRABCG2
SCHEMBL5865262 0.86 EGFR (0.81) JAK3MKNK1EGFRKDRABCG2
SCHEMBL5570070 0.85 EGFR (0.85) JAK3MKNK1EGFRKDRABCG2
SCHEMBL5864645 0.84 EGFR (0.67) JAK3MKNK1EGFRKDRABCG2
SCHEMBL5467825 0.83 EGFR (1.00) JAK3MKNK1EGFRKDRABCG2
Hydrochloric Acid SCHEMBL5479908 0.82 EGFR (0.97) JAK3MKNK1EGFRKDRABCG2
SCHEMBL5864737 0.82 EGFR (0.78) JAK3MKNK1EGFRKDRABCG2
SCHEMBL29711485 0.82 JAK3 (1.00) JAK3MKNK1EGFRKDRABCG2
SCHEMBL20812874 0.82 EGFR (0.80) JAK3MKNK1EGFRKDRABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 US claimed
JP-2002540103-A 2002-11-26 JP claimed
US-20020137757-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2002-09-26 US claimed
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof PARKER HUGHES INSTITUTE 2002-08-15 US claimed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP claimed
EP-1162974-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP claimed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 US claimed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 US claimed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO claimed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO claimed
US-7038049-B2 Haloanilino quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2006-05-02 US disclosed
US-20050075353-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2005-04-07 US disclosed
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 US disclosed
US-6638939-B2 Anticancer agents PARKER HUGHES INSTITUTE 2003-10-28 US disclosed
US-20020137757-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2002-09-26 US disclosed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP disclosed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 US disclosed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 US disclosed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075353-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT JAK3 321/4885MKNK1 1914/4885EGFR 1931/4885
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof CMA1, MAST3, MAST1 JAK3 339/4885MKNK1 1328/4885EGFR 3336/4885
US-20020137757-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT JAK3 321/4885MKNK1 1914/4885EGFR 1931/4885
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof HRH2, HNMT, HRH4 JAK3 701/4885MKNK1 2106/4885EGFR 1601/4885
US-20010016588-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT JAK3 321/4885MKNK1 1914/4885EGFR 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.